# An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

> **NCT05363319** · — · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 500 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Platinum-based chemotherapy

## Key facts

- **NCT ID:** NCT05363319
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2028-10-30
- **Final completion:** 2028-10-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363319, "An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT05363319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*